Publication | Open Access

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Met AmplificationMedicinePathologyInsight 2Cancer TreatmentCancer GeneticsFirst-line OsimertinibOncologyRadiation OncologyLung CancerMolecular Oncology